Drug Information

General Information
Drug ID
DR01395
Drug Name
Triprolidine
Synonyms
Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride
Drug Type
Small molecular drug
Indication Allergic rhinitis [ICD11:CA08.0] Approved [1]
Therapeutic Class
Antiallergic Agents
Structure
3D MOL 2D MOL
Formula
C19H22N2
Canonical SMILES
CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3
InChI
InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
InChIKey
CBEQULMOCCWAQT-WOJGMQOQSA-N
CAS Number
CAS 486-12-4
Pharmaceutical Properties Molecular Weight 278.4 Topological Polar Surface Area 16.1
Heavy Atom Count 21 Rotatable Bond Count 4
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 2
XLogP
3.9
PubChem CID
5282443
PubChem SID
7980840 ,8077587 ,11038508 ,14897473 ,17448291 ,26751829 ,39315888 ,46505403 ,47291040 ,47440150 ,47736373 ,47736374 ,47885310 ,47885311 ,48110356 ,48334387 ,49698410 ,49855442 ,50104523 ,50104524 ,50104525 ,57309729 ,75497893 ,85209605 ,85788432 ,90341007 ,92308937 ,93166727 ,96025331 ,103223987 ,104133962 ,113857221 ,124610340 ,124886935 ,124886936 ,134338323 ,134975511 ,135651281 ,137002512 ,138314072 ,140229550 ,144204470 ,160963773 ,170464931 ,172820007 ,175267951 ,176483998 ,179113821 ,181753769 ,181855806
ChEBI ID
CHEBI:84116
TTD Drug ID
D0E8CI
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Triprolidine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos. 2007 Aug;35(8):1341-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.